RICE Pharmaceuticals Overview
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
RICE Pharmaceuticals General Information
Description
Developer of remyelination therapies for neurodegenerative diseases based in the United States. The company's drug pipeline includes PDE4D inhibitors designed to repair myelin damage in conditions such as multiple sclerosis by stimulating the cells responsible for myelin production, enabling neurologists and specialty care providers to offer treatment options that target myelin restoration in patients where existing therapies manage symptoms but do not repair underlying nerve damage.
Contact Information
Website
www.ricepharma.comCorporate Office
- Amsterdam
- Netherlands
Corporate Office
- Amsterdam
- Netherlands
RICE Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 29-Oct-2026 | Completed | Out of Business | |||
| 1. Seed Round | 06-Jun-2025 | Completed | Startup |
RICE Pharmaceuticals FAQs
-
Where is RICE Pharmaceuticals headquartered?
RICE Pharmaceuticals is headquartered in Amsterdam, Netherlands.
-
What industry is RICE Pharmaceuticals in?
RICE Pharmaceuticals’s primary industry is Drug Discovery.
-
Is RICE Pharmaceuticals a private or public company?
RICE Pharmaceuticals is a Private company.
-
What is RICE Pharmaceuticals’s current revenue?
The current revenue for RICE Pharmaceuticals is .
-
How much funding has RICE Pharmaceuticals raised over time?
RICE Pharmaceuticals has raised $150K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process